Cibus, Inc. (CBUS)

Cibus, Inc. (CBUS) Healthcare & Pipeline Overview

Cibus, Inc. is an agricultural biotechnology firm developing and licensing plant traits aimed at improving crop yields and promoting sustainable agricultural practices. The company focuses on traits that reduce reliance on chemicals and fossil fuels, positioning it within the evolving landscape of sustainable agriculture and biotechnology.

What Is the Investment Thesis for CBUS?

Cibus, Inc. presents a compelling investment thesis centered on its innovative approach to agricultural biotechnology. The company's focus on developing and licensing plant traits that enhance crop productivity and promote sustainability aligns with the growing global demand for efficient and environmentally responsible farming practices. A key value driver is Cibus's ability to generate revenue through royalties from seed companies that incorporate its traits into their products. The company’s gross margin of 23.9% indicates potential for profitability as adoption of its traits increases. Upcoming catalysts include the potential commercialization of new traits and expansion into new markets. However, investors should be aware of the risks associated with the biotechnology sector, including regulatory hurdles and competition from larger agricultural companies. With a market cap of $64.14M and a beta of 1.93, Cibus represents a high-risk, high-reward investment opportunity within the agricultural technology space.

Based on FMP financials and quantitative analysis

CBUS Key Highlights

• Cibus operates in the agricultural biotechnology sector, focusing on developing and licensing plant traits.
• The company's primary focus is on productivity traits that enhance crop yields and reduce the use of chemicals and fertilizers.
• Cibus also develops sustainable ingredients to replace fossil fuel-based alternatives, aligning with environmental sustainability goals.
• Cibus's business model involves licensing its proprietary traits to seed companies for royalties.
• The company's gross margin is 23.9%, indicating potential for profitability.

Who Are CBUS's Competitors?

CBUS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CBUS's Key Strengths?

• Innovative plant trait technology.
• Focus on sustainable agriculture.
• Royalty-based revenue model.
• Experienced management team.

What Are CBUS's Weaknesses?

• Relatively small market capitalization.
• Limited financial resources compared to larger competitors.
• Dependence on licensing agreements for revenue.
• Negative profit margin.

What Could Drive CBUS Stock Higher?

• Potential commercialization of new plant traits.
• Expansion into new geographic markets.
• Securing new licensing agreements with seed companies.
• Advancements in research and development of sustainable ingredients.

What Are the Key Risks for CBUS?

• Financial-distress signal — its Altman Z-Score of -4.27 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from larger agricultural companies.
• Regulatory hurdles and approval processes.
• Dependence on licensing agreements for revenue.
• Fluctuations in commodity prices.
• Technological advancements by competitors.

What Are the Growth Opportunities for CBUS?

• Expansion into New Markets: Cibus has the opportunity to expand its market reach by targeting new geographic regions and crop types. The global market for agricultural biotechnology is vast, with significant potential in emerging economies. By tailoring its plant traits to specific regional needs and crop varieties, Cibus can tap into new revenue streams and diversify its customer base. This expansion could involve establishing partnerships with local seed companies or developing traits specifically suited to the agricultural practices of these regions. The timeline for this growth opportunity is ongoing, with continuous efforts to identify and penetrate new markets.
• Development of Novel Plant Traits: Cibus can drive growth by investing in the research and development of novel plant traits that address unmet needs in the agricultural sector. This includes traits that enhance drought resistance, improve nutrient utilization, or increase resistance to pests and diseases. By staying at the forefront of innovation, Cibus can maintain a competitive edge and attract new licensing agreements with seed companies. The market for advanced plant traits is constantly evolving, with ongoing demand for solutions that improve crop performance and reduce environmental impact. The timeline for this growth opportunity is ongoing, with continuous research and development efforts.
• Strategic Partnerships and Collaborations: Cibus can accelerate its growth by forming strategic partnerships and collaborations with other companies in the agricultural sector. This includes partnerships with seed companies, agricultural input suppliers, and research institutions. By leveraging the expertise and resources of its partners, Cibus can expand its product portfolio, access new markets, and accelerate the commercialization of its plant traits. The market for agricultural technologies is highly collaborative, with companies often working together to develop and deliver innovative solutions. The timeline for this growth opportunity is ongoing, with continuous efforts to identify and establish strategic partnerships.
• Focus on Sustainable Ingredients: Cibus has a significant growth opportunity in the development and commercialization of sustainable ingredients that replace fossil fuel-based alternatives. As corporations and consumers increasingly seek environmentally friendly products, the demand for sustainable ingredients is growing rapidly. Cibus can capitalize on this trend by developing plant traits that produce sustainable oils, proteins, and other ingredients. The market for sustainable ingredients is vast and growing, with potential applications in food, cosmetics, and industrial products. The timeline for this growth opportunity is ongoing, with continuous research and development efforts focused on sustainable ingredients.
• Licensing Agreements and Royalty Revenue: Cibus's business model relies on licensing its plant traits to seed companies for royalties. The company can drive growth by increasing the number of licensing agreements and expanding the adoption of its traits by seed companies. This involves actively marketing its traits to potential licensees, providing technical support, and demonstrating the value of its traits through field trials and performance data. The market for plant traits is competitive, but Cibus can differentiate itself by offering innovative traits that address specific needs and provide significant benefits to farmers. The timeline for this growth opportunity is ongoing, with continuous efforts to secure new licensing agreements and expand royalty revenue.

What Opportunities Does CBUS Have?

• Expansion into new geographic markets.
• Development of new plant traits.
• Strategic partnerships and collaborations.
• Increasing demand for sustainable ingredients.

What Threats Does CBUS Face?

• Competition from larger agricultural companies.
• Regulatory hurdles and approval processes.
• Fluctuations in commodity prices.
• Technological advancements by competitors.

What Are CBUS's Competitive Advantages?

• Proprietary Technology: Cibus possesses patented plant trait technology.
• Focus on Sustainable Agriculture: Growing demand for sustainable agricultural practices.
• Royalty-Based Revenue Model: Recurring revenue stream from licensing agreements.

What Does CBUS Do?

Cibus, Inc., founded with the vision of revolutionizing agriculture through advanced biotechnology, develops and licenses plant traits to seed companies. The company's core focus is on enhancing crop productivity and promoting sustainable agricultural practices. Cibus operates primarily in two key areas: productivity traits designed to increase yields and reduce the need for crop protection chemicals and fertilizers, and sustainable ingredients intended to replace fossil fuel-based alternatives and mitigate greenhouse gas emissions. By licensing its proprietary traits to seed companies, Cibus aims to integrate its innovations into a wide range of crops, thereby maximizing its impact on global agriculture. The company's headquarters are located in San Diego, California, reflecting its commitment to innovation and technological advancement in the agricultural sector. Cibus's approach involves leveraging its expertise in plant genetics to create traits that not only benefit farmers through improved crop performance but also contribute to a more sustainable and environmentally friendly food production system. This dual focus on productivity and sustainability positions Cibus as a key player in the future of agriculture, addressing the growing demand for efficient and eco-conscious farming practices.

What Products and Services Does CBUS Offer?

• Develops plant traits to enhance crop productivity.
• Licenses plant traits to seed companies for royalties.
• Focuses on traits that increase crop yields.
• Develops traits that reduce the use of crop protection chemicals and fertilizers.
• Creates sustainable ingredients to replace fossil fuel-based alternatives.
• Aims to reduce greenhouse gas emissions through sustainable agricultural practices.
• Conducts research and development in plant genetics and biotechnology.

How Does CBUS Make Money?

• Develops proprietary plant traits through advanced biotechnology.
• Licenses these traits to seed companies.
• Generates revenue through royalty payments based on seed sales incorporating Cibus's traits.

What Industry Does CBUS Operate In?

Cibus, Inc. operates within the agricultural biotechnology industry, a sector characterized by rapid innovation and increasing demand for sustainable farming solutions. The global market for agricultural biotechnology is driven by the need to enhance crop yields, reduce environmental impact, and improve food security. Cibus competes with larger agricultural companies and other biotechnology firms in the development and licensing of plant traits. The company's focus on sustainable ingredients positions it favorably within the market, as consumers and corporations increasingly seek alternatives to fossil fuel-based products. The industry is subject to regulatory scrutiny and requires significant investment in research and development.

Who Are CBUS's Key Customers?

• Seed companies that incorporate Cibus's plant traits into their seed products.
• Farmers who benefit from improved crop yields and reduced input costs.
• Corporations seeking sustainable ingredients for their products.

Cibus, Inc. (CBUS) Valuation Context

Valued at $64.14M, CBUS is classified as a micro-cap stock. Relative to its peer group, CBUS's quantitative score of 17/100 is below the peer average of 63/100.

CBUS Revenue & Earnings Trend

In Q1 2026, CBUS generated $1.7M in top-line revenue, marking a sequential increase of 59.0%. The company recorded a net loss of $21.2M, with diluted EPS of $-0.33. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, CBUS averaged $-0.44 in diluted EPS.

Company Profile

Cibus, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Peter R. Beetham. CBUS has traded publicly since 2017.

Key Financial Metrics

Return on assets is -31.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -90.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Cibus, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.27 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Cibus, Inc. revenue of about $8.0M for fiscal 2026, with EPS near $-1.22. The estimate reflects 3 contributing analysts.

CBUS Financials

CBUS Latest News

CBUS Analyst Consensus

CBUS MoonshotScore

Cibus, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources